Monoclonal antibody CDMOs in Europe: 36 compared (2026)
36 of the 255 contract development and manufacturing organisations in A4BEE’s European census list monoclonal antibody manufacturing among their capabilities. The largest, with revenue over €1bn, are AGC Biologics, Boehringer BioXcellence, BSP Pharmaceuticals, Fareva, Fujifilm Diosynth, Gedeon Richter and 4 more. 8 sit between €250m and €1bn and 18 are smaller or niche.
By ownership: 17 family-owned, 2 private equity, 8 listed, 8 part of a pharma or industrial group and 1 state-owned. They are spread across 16 countries, led by Germany (4), Poland (4), the United Kingdom (4), Italy (3) and the Netherlands (3). 13 of the 36 rows rest on audited reports or official company disclosures; the rest come from secondary sources or estimates.
36 companies
Monoclonal antibody CDMOs in Europe
| Company | Country | Ownership | Size | Revenue (as reported) | Modalities | Data |
|---|---|---|---|---|---|---|
| AGC BiologicsCopenhagen site expanded to 16,000 L single-use; broad multi-modality platform. | Copenhagen, Denmark | Part of a pharma or industrial groupAGC Inc. | Tier 1 | ~US$1.2 bn (global) | Monoclonal antibody, Microbial and protein, mRNA and LNP, Viral vector and vaccine, Cell and gene therapy | medium |
| Boehringer BioXcellenceUp to ~185,000 L mammalian capacity; a strategic pharma-owned biologics powerhouse. | Biberach, Germany | Part of a pharma or industrial groupBoehringer Ingelheim | Tier 1 | n/d (group €27.8 bn) | Monoclonal antibody, Microbial and protein, Sterile fill-finish | medium |
| BSP PharmaceuticalsLeading oncology CDMO: ADC conjugation + highly-potent aseptic fill-finish from clinical to commercial. Serves ~80 countries. | Latina, Italy | Family-ownedBraca family | Tier 1 | €532.7 m (2024) | Sterile fill-finish, Antibody-drug conjugate (ADC), Monoclonal antibody, Oral solid dose | high |
| Fareva | Luxembourg, Luxembourg | Family-owned | Tier 1 | ~€2.2 bn | Sterile fill-finish, Oral solid dose, Small-molecule API, Monoclonal antibody | medium |
| Fujifilm Diosynth~US$8 bn global capex; Hillerød (DK) site runs 12 bioreactors. | Billingham, United Kingdom | Part of a pharma or industrial groupFujifilm | Tier 1 | ~US$2.0 bn (global) | Biologics and biosimilars, Monoclonal antibody, Viral vector and vaccine, Cell and gene therapy | medium |
| Gedeon RichterPrimarily own-product/biosimilar pharma, but runs a real biologics CDMO arm (mammalian DS + fill-finish) and microbial CDMO via Richter-Helm. Group figures mostly non-CDMO. | Budapest, Hungary | Listed | Tier 1 | ~€2.1 bn (2023, group) | Biologics and biosimilars, Monoclonal antibody, Microbial and protein, Sterile fill-finish, Small-molecule API | high |
| Insud Pharma (Chemo)Group-level entity. Chemo industrial division provides CMO/CDMO across most dosage forms incl. injectables. Parent of Liconsa and León Farma. | Madrid, Spain | Family-ownedGrupo Insud | Tier 1 | not disclosed | Small-molecule API, Oral solid dose, Sterile fill-finish, Biologics and biosimilars, Monoclonal antibody | high |
| LonzaIntegrated Biologics grew +32.2% CER in 2025; the sector's clear scale + digital leader. | Basel, Switzerland | Listed | Tier 1 | CHF 6.5 bn (2025) | Biologics and biosimilars, Monoclonal antibody, Antibody-drug conjugate (ADC), Small-molecule API, Cell and gene therapy, Microbial and protein | high |
| mAbxienceBiosimilar developer and biologics CDMO; fully single-use technology at León. CDMO services confirmed. | León, Spain | Part of a pharma or industrial groupFresenius Kabi | Tier 1 | not disclosed | Monoclonal antibody, Biologics and biosimilars, Microbial and protein | high |
| SandozBiosimilars leader; CDMO/CMO is a secondary activity to its own portfolio. | Basel, Switzerland | Listed | Tier 1 | n/d | Biologics and biosimilars, Monoclonal antibody | low |
| AbzenaIntegrated biologics / bioconjugate / ADC CDMO+CRO, UK-founded but increasingly US-centred — European-HQ status borderline. Fills the ADC/bioconjugation gap. | Cambridge, United Kingdom | Private equityWelsh, Carson, Anderson & Stowe | Tier 2 | not disclosed | Biologics and biosimilars, Monoclonal antibody, Antibody-drug conjugate (ADC) | low |
| AlvotechReykjavik-based vertically-integrated biosimilars company (Nasdaq: ALVO). Core is its own biosimilar mAbs; 'Alvotech Contract Services' offers third-party biologics CDMO work. | Reykjavik, Iceland | Listed | Tier 2 | not disclosed | Monoclonal antibody, Biologics and biosimilars, Sterile fill-finish | medium |
| Cobra Biologics (Charles River)Sweden-registered mammalian mAb/recombinant-protein site, now part of US Charles River. Standalone CDMO branding uncertain. | Södertälje, Sweden | Part of a pharma or industrial groupCharles River | Tier 2 | not disclosed | Monoclonal antibody, Biologics and biosimilars | medium |
| Haupt Pharma LatinaAenova Group's designated central sterile site. Third-party sterile fill-finish plus beta-lactam injectables and oral solids. | Latina, Italy | Part of a pharma or industrial groupAenova Group | Tier 2 | not disclosed | Sterile fill-finish, Oral solid dose, Monoclonal antibody, Peptide, Biologics and biosimilars | low |
| Just-Evotec BiologicsEvotec's biologics CDMO arm; J.POD Toulouse opened 2024 as its first EU facility. Distinct from the small-molecule Aptuit (Evotec) site. | Toulouse, France | ListedEvotec | Tier 2 | not disclosed | Monoclonal antibody, Biologics and biosimilars | medium |
| Merck KGaA CDMOLife-Science CDMO arm covering biologics, ADC/HPAPI, viral vectors and LNP (via Exelead). | Darmstadt, Germany | ListedE. Merck KG | Tier 2 | not disclosed | Monoclonal antibody, Biologics and biosimilars, Antibody-drug conjugate (ADC), Viral vector and vaccine, mRNA and LNP | medium |
| NorthX BiologicsBiologics CDMO built on the former Cobra Biologics Matfors site; Swedish national innovation hub for ATMPs. | Matfors, Sweden | Private equityFlerie Invest | Tier 2 | not disclosed | Microbial and protein, Biologics and biosimilars, mRNA and LNP, Viral vector and vaccine, Cell and gene therapy, Monoclonal antibody, Sterile fill-finish | low |
| Rentschler BiopharmaComplex-protein pure-play; exited CGT in 2025 to refocus on biologics. | Laupheim, Germany | Family-owned | Tier 2 | ~US$296 m (2025) | Biologics and biosimilars, Monoclonal antibody, Microbial and protein | medium |
| Batavia BiosciencesBiologics CDMO: viral vaccines/vectors, oncolytic viruses, proteins/antibodies; proprietary yield platforms. Owned by CJ (2021). | Leiden, Netherlands | Part of a pharma or industrial groupCJ CheilJedang | Tier 3 | not disclosed | Biologics and biosimilars, Viral vector and vaccine, Monoclonal antibody | high |
| Bilthoven BiologicalsVaccine CDMO (inactivated polio, viral-vector/Vero platforms; also mAbs). Owned by Serum Institute of India. | Bilthoven, Netherlands | Family-ownedSerum Institute of India | Tier 3 | not disclosed | Viral vector and vaccine, Biologics and biosimilars, Monoclonal antibody | high |
| BioneerCombined CRO + CDMO; process dev and GMP/non-GMP manufacturing of recombinant proteins/enzymes. Not-for-profit GTS institute, DTU subsidiary. | Hørsholm, Denmark | State-ownedTechnical University of Denmark | Tier 3 | not disclosed | Biologics and biosimilars, Microbial and protein, Monoclonal antibody | high |
| Celonic | Basel, Switzerland | Family-ownedJRS Group | Tier 3 | n/d | Monoclonal antibody, Biologics and biosimilars, Cell and gene therapy | medium |
| CuridaFrom a 2015 buyout of Takeda's Elverum sterile-liquids plant. BFS + nasal-spray fill-finish CDMO, plus a small Bio-CDMO unit (mAbs for preclinical/diagnostic use). | Elverum, Norway | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Monoclonal antibody, Biologics and biosimilars | high |
| GTP BiowaysBiologics CDMO (mAbs, proteins, nanodrugs, ADCs, fill-finish). Acquired by Italy's Olon; now Olon France. | Toulouse, France | Part of a pharma or industrial groupOlon Group | Tier 3 | ~€12 m | Monoclonal antibody, Biologics and biosimilars, Antibody-drug conjugate (ADC), Microbial and protein, Sterile fill-finish | high |
| HALIXMammalian biologics CDMO: viral vectors, vaccines, recombinant proteins (1,000L SUB). Made AstraZeneca's COVID vaccine. | Leiden, Netherlands | Family-ownedDroege Group | Tier 3 | not disclosed | Viral vector and vaccine, Biologics and biosimilars, Monoclonal antibody | high |
| IBI LorenziniAseptic manufacturing of sterile injectables (specialist in sterile penicillins/cephalosporins) plus oral, topical and biotech. | Aprilia, Italy | Family-ownedIbigen Group | Tier 3 | not disclosed | Sterile fill-finish, Oral solid dose, Biologics and biosimilars, Monoclonal antibody, Peptide | high |
| IcosagenEnd-to-end mammalian biologics CRDMO: antibody discovery/engineering, CHO cell-line/process dev, and a new GMP facility (50–1000L single-use) for Phase I/II drug substance. | Tartu, Estonia | Family-owned | Tier 3 | not disclosed | Biologics and biosimilars, Monoclonal antibody | high |
| MabionPivoted from biosimilar developer to biologics CDMO; anchor Novavax COVID-antigen contract + Sartorius cooperation. | Konstantynów Łódzki, Poland | Listed | Tier 3 | n/d (Novavax-driven, volatile) | Biologics and biosimilars, Monoclonal antibody, Sterile fill-finish | low |
| Northway BiotechCEE cost-competitive biologics CDMO scaling to 5,000 L stainless steel. | Vilnius, Lithuania | Family-owned | Tier 3 | n/d | Monoclonal antibody, Microbial and protein, Biologics and biosimilars, Sterile fill-finish, Viral vector and vaccine, Cell and gene therapy | medium |
| Nova LaboratoriesIndependent aseptic-processing CDMO + 'Specials' supplier; sterile fill-finish for clinical-trial medicines. | Leicester, United Kingdom | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Monoclonal antibody, Biologics and biosimilars, Microbial and protein | medium |
| Polpharma BiologicsJune 2025 demerger: biosimilars brand stays as Polpharma Biologics (operating from Switzerland); the CDMO becomes Rezon Bio. | Gdańsk, Poland | Family-ownedPolpharma | Tier 3 | ~US$18–100 m est. | Biologics and biosimilars, Monoclonal antibody, Microbial and protein | low |
| ProBioGenIndependent biologics CDMO (proteins/antibodies, viral vectors, vaccines); Charité spin-off, founded 1994. | Berlin, Germany | Family-owned | Tier 3 | not disclosed | Monoclonal antibody, Biologics and biosimilars, Viral vector and vaccine | medium |
| Pure BiologicsAntibody/aptamer discovery + protein production (CRO). | Wrocław, Poland | Listed | Tier 3 | ~US$15 m est. | Monoclonal antibody, Biologics and biosimilars | medium |
| Rezon BioCDMO carved out of Polpharma Biologics (June 2025); positions to be Europe's most cost-competitive CDMO. | Gdańsk, Poland | Family-ownedPolpharma | Tier 3 | n/d | Biologics and biosimilars, Monoclonal antibody, Microbial and protein | low |
| Symbiosis Pharmaceutical ServicesIndependent sterile aseptic fill-finish CDMO (clinical + commercial): mAbs, ATMPs, viral vectors, ADCs, vaccines. FDA-inspected. | Stirling, United Kingdom | Family-owned | Tier 3 | not disclosed | Sterile fill-finish, Monoclonal antibody, Antibody-drug conjugate (ADC), Biologics and biosimilars, Cell and gene therapy, Small-molecule API | medium |
| Wellgem BiopharmaBiologics contract dev/manufacturing: mammalian + microbial cell-line/process dev, cGMP cell banking, Phase II pilot facility. Newer entrant. | Vilnius, Lithuania | Family-owned | Tier 3 | not disclosed | Biologics and biosimilars, Monoclonal antibody, Microbial and protein, Viral vector and vaccine, Cell and gene therapy | medium |
Size: Tier 1 (revenue over €1bn) · Tier 2 (€250m–€1bn) · Tier 3 (under €250m or niche).
Revenue, staff and site figures are as reported and mix audited accounts with commercial estimates, which are often wrong for private companies. Each row carries a confidence mark; verify a figure before quoting it.
Browse the census
Other European CDMO lists
By country
- CDMOs in Italy (31)
- CDMOs in Spain (30)
- CDMOs in Germany (28)
- CDMOs in the United Kingdom (25)
- CDMOs in France (15)
- CDMOs in Switzerland (14)
- CDMOs in Poland (11)
- CDMOs in Belgium (9)
- CDMOs in Sweden (9)
- CDMOs in Greece (8)
- CDMOs in Ireland (8)
- CDMOs in the Netherlands (8)
- CDMOs in Portugal (8)
- CDMOs in Denmark (7)
- CDMOs in Austria (5)
- CDMOs in Finland (5)
- CDMOs in Norway (5)
- CDMOs in Czechia (4)
- CDMOs in Lithuania (4)
- CDMOs in Bulgaria (3)
By modality
- Small-molecule API CDMOs in Europe (107)
- Oral solid dose CDMOs in Europe (94)
- Sterile fill-finish CDMOs in Europe (106)
- Biologics and biosimilars CDMOs in Europe (66)
- Monoclonal antibody CDMOs in Europe
- Antibody-drug conjugate (ADC) CDMOs in Europe (15)
- Cell and gene therapy CDMOs in Europe (29)
- mRNA and LNP CDMOs in Europe (22)
- Viral vector and vaccine CDMOs in Europe (32)
- Microbial and protein CDMOs in Europe (34)
- Peptide CDMOs in Europe (24)